Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Stock Has Consensus Target Price of $56.25 According to Brokerages

Key Points

• Sensei Biotherapeutics has a “Moderate Buy” consensus rating from 15 brokerages, with 11 buys, two strong buys, one hold and one sell. The average 12-month price target is $56.25.
• Shares opened at $29.05 after declining 7.9%, well below the analyst target range of roughly $56–$60. The stock has traded between $7.45 and $42.14 over the past year.
• The company reported a quarterly loss of $2.84 per share, beating the consensus estimate of a $5.04 loss. Insiders have recently purchased 13,634 shares valued at approximately $326,118.

Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fifteen brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eleven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $56.25.

Several equities analysts recently commented on FTH shares. Needham & Company LLC assumed coverage on Sensei Biotherapeutics in a research report on Friday, August 21st. They set a "buy" rating and a $56.00 target price for the company. Wall Street Zen raised Sensei Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 22nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Oppenheimer initiated coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They set an "outperform" rating and a $60.00 price objective for the company. Finally, Robert W. Baird began coverage on shares of Sensei Biotherapeutics in a research report on Friday, June 26th. They issued an "outperform" rating and a $57.00 price objective on the stock.

Sensei Biotherapeutics Trading Down 7.9%

Shares of NASDAQ:FTH opened at $29.05 on Friday. The company's 50 day moving average price is $32.03. The stock has a market capitalization of $750.65 million, a PE ratio of -0.21 and a beta of -0.28. Sensei Biotherapeutics has a 12 month low of $7.45 and a 12 month high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. On average, equities analysts anticipate that Sensei Biotherapeutics will post -13.69 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Brian C. Stephenson purchased 7,803 shares of the business's stock in a transaction on Tuesday, June 30th. The stock was acquired at an average price of $24.25 per share, with a total value of $189,222.75. Following the purchase, the chief financial officer directly owned 41,688 shares in the company, valued at approximately $1,010,934. This represents a 23.03% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders have purchased 13,634 shares of company stock valued at $326,118. 7.00% of the stock is owned by insiders.

Institutional Trading of Sensei Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in FTH. Vivo Capital LLC purchased a new position in Sensei Biotherapeutics in the first quarter worth $22,758,000. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics during the first quarter valued at about $4,188,000. Alyeska Investment Group L.P. purchased a new stake in Sensei Biotherapeutics during the second quarter valued at about $3,610,000. Bank of America Corp DE lifted its stake in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company's stock worth $1,010,000 after purchasing an additional 20,525 shares during the last quarter. Hedge funds and other institutional investors own 10.50% of the company's stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company's research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei's technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.